FDA Has Assigned A Standard Review And A Prescription Drug User Fee Act Action Date Of June 16, 2024 For Geron's New Drug Application For Imetelstat For Transfusion-dependent Anemia In Patients With Lower-risk Myelodysplastic Syndromes
Portfolio Pulse from Benzinga Newsdesk
The FDA has assigned a standard review and a Prescription Drug User Fee Act action date of June 16, 2024, for Geron's new drug application for Imetelstat for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes. The FDA also plans to hold an advisory committee meeting as part of the NDA review.
August 22, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's new drug application for Imetelstat has been assigned a review date by the FDA. This could potentially impact the company's stock in the short term.
The FDA's decision to assign a review date for Geron's new drug application is a significant step in the drug approval process. This news could potentially lead to increased investor confidence in Geron, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100